Ameet Mallik

Ameet Mallik is the President and Chief Executive Officer of ADC Therapeutics, a biotechnology company focused on developing next-generation targeted antibody-drug conjugates for cancer treatment. He joined ADC Therapeutics in May 2022, succeeding co-founder Chris Martin, and has since been instrumental in driving the company's growth and innovation in oncology therapies.1 3

Background and Career

Education: Mallik holds an MBA from The Wharton School at the University of Pennsylvania, along with an M.S. in Biotechnology and a B.S. in Chemical Engineering from Northwestern University.1 2
Professional Experience:
- Before joining ADC Therapeutics, Mallik served as the CEO of Rafael Holdings, a company dedicated to cancer and immune metabolism therapeutics.2
- He spent over 16 years at Novartis in various leadership roles, including Executive Vice President and Head of U.S. Oncology. His responsibilities encompassed commercial operations in oncology, global marketing, and strategic planning.1 4
- Earlier in his career, he worked as an Associate Principal at McKinsey & Company and held significant positions at Sandoz, a Novartis division, where he was the Global Head of Biopharmaceuticals & Oncology Injectables.2 4

Current Role

As CEO of ADC Therapeutics, Mallik is focused on enhancing the company's product offerings and expanding its pipeline to address unmet medical needs in cancer treatment. He emphasizes the importance of developing effective therapies while also addressing challenges related to accessibility and cost.5 Additionally, he serves on the boards of Atara Biotherapeutics and Rafael Holdings, contributing his expertise to multiple organizations within the biotechnology sector.2 4

Personal Insights

Mallik's leadership style is characterized by a commitment to innovation and collaboration within the biotechnology field. He actively engages with academic institutions to share insights on navigating careers in biotechnology and emphasizes the significance of networking for emerging professionals in the industry.5